China Oncology Companion Diagnostic Market Size & Outlook
- Clinical Diagnostics
- In Vitro Diagnostics
- oncology companion diagnostics market
- In Vitro Diagnostics
Global Market
Related Markets
Ask a question about the oncology companion diagnostics market
China oncology companion diagnostic market highlights
- The China oncology companion diagnostic market generated a revenue of USD 193.0 million in 2023 and is expected to reach USD 448.4 million by 2030.
- The China market is expected to grow at a CAGR of 12.8% from 2024 to 2030.
- In terms of segment, product was the largest revenue generating product & service in 2023.
- Service is the most lucrative product & service segment registering the fastest growth during the forecast period.
Oncology companion diagnostic market data book summary
| Market revenue in 2023 | USD 193.0 million |
| Market revenue in 2030 | USD 448.4 million |
| Growth rate | 12.8% (CAGR from 2024 to 2030) |
| Largest segment | Product |
| Fastest growing segment | Service |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Product, Service |
| Key market players worldwide | Agilent Technologies Inc, Illumina Inc, Qiagen NV, Thermo Fisher Scientific Inc, ARUP Laboratories, Abbott Laboratories, Myriad Genetics Inc, BioMerieux SA, Roche Holding AG ADR |
Other key industry trends
- In terms of revenue, China accounted for 4.0% of the global oncology companion diagnostic market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, Japan oncology companion diagnostic market is projected to lead the regional market in terms of revenue in 2030.
- China is the fastest growing regional market in Asia Pacific and is projected to reach USD 448.4 million by 2030.
The oncology companion diagnostic market in China has witnessed significant growth due to lifestyle changes, dietary habits, and an aging population. Companies are engaged in developing new therapies to treat oncology CDx. In addition, companies have entered into collaborations and partnership agreements to provide MCED tests in the country.
For instance, in April 2022, AstraZeneca and Amoy Diagnostics signed a Master Collaboration Agreement. Through this agreement, the parties can work together to develop and commercialize AmoyDx tests, which might be used worldwide as CDx for any kind of indication or biomarker associated with AstraZeneca medications.
The initial projects under the agreement include the co-development of a CDx test to identify patients with Homologous Recombination Repair (HRR) gene mutations in prostate cancer in China, Japan, and the EU, as well as a CDx test to identify patients with BRCA gene mutations in breast cancer in the EU for Lynparza (olaparib) monotherapy. 3 days are allotted for the completion of the HRR or BRCA gene mutation testing due to the AmoyDx decentralized CDx.
No credit card required*
Publish Date: Jan 17, 2025
Customize the Report
20% free customization
- Include
- Countries, segments, points
- Tailor
- To your product definition
- Extend
- Deeper competitor detail
- Or
- A fully bespoke study
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Oncology Companion Diagnostics Market
Oncology Companion Diagnostics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Roche Holding AG ADR | View profile | 103,605 | Grenzacherstrasse 124, Basel, Switzerland, 4070 | www.roche.com |
| Abbott Laboratories | View profile | 114,000 | 100 Abbott Park Road, Abbott Park, IL, United States, 60064-6400 | www.abbottinvestor.com |
| BioMerieux SA | View profile | 13,982 | Marcy l’Etoile, Lyon, France, 69280 | www.biomerieux.com |
| Thermo Fisher Scientific Inc | View profile | 122,000 | 168 Third Avenue, Waltham, MA, United States, 02451 | www.thermofisher.com |
| Illumina Inc | View profile | 9,300 | 5200 Illumina Way, San Diego, CA, United States, 92122 | www.illumina.com |
| Agilent Technologies Inc | View profile | 17,700 | 5301 Stevens Creek Boulevard, Santa Clara, CA, United States, 95051 | www.agilent.com |
| Qiagen NV | View profile | 5,900 | Hulsterweg 82, Venlo, LI, Netherlands, 5912 PL | www.qiagen.com |
| Myriad Genetics Inc | View profile | 2,700 | 320 Wakara Way, Salt Lake City, UT, United States, 84108 | www.myriad.com |
| ARUP Laboratories | View profile | 1001-5000 | Salt Lake City, Utah, United States, North America | www.aruplab.com |
China oncology companion diagnostics market
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Oncology Companion Diagnostic Market Outlook will help companies and investors design strategic landscapes.
Product was the largest segment with a revenue share of 66.48% in 2023.
Horizon Databook has segmented the China oncology companion diagnostic market based on product, service covering the revenue growth of each sub-segment from 2018 to 2030.
The oncology companion diagnostic market in China has witnessed significant growth due to lifestyle changes, dietary habits, and an aging population. Companies are engaged in developing new therapies to treat oncology CDx. In addition, companies have entered into collaborations and partnership agreements to provide MCED tests in the country.
For instance, in April 2022, AstraZeneca and Amoy Diagnostics signed a Master Collaboration Agreement. Through this agreement, the parties can work together to develop and commercialize AmoyDx tests, which might be used worldwide as CDx for any kind of indication or biomarker associated with AstraZeneca medications.
The initial projects under the agreement include the co-development of a CDx test to identify patients with Homologous Recombination Repair (HRR) gene mutations in prostate cancer in China, Japan, and the EU, as well as a CDx test to identify patients with BRCA gene mutations in breast cancer in the EU for Lynparza (olaparib) monotherapy. 3 days are allotted for the completion of the HRR or BRCA gene mutation testing due to the AmoyDx decentralized CDx.
- China Oncology Companion Diagnostic Market Product & Service Outlook (Revenue, USD Million , 2018-2030)
- Product
- Service
- China Oncology Companion Diagnostic Market End Use Outlook (Revenue, USD Million , 2018-2030)
- Hospital
- Pathology/Diagnostic laboratory
- Academic medical center
- China Oncology Companion Diagnostic Market Disease Type Outlook (Revenue, USD Million , 2018-2030)
- Breast cancer
- Non-small cell lung cancer
- Colorectal cancer
- Leukemia
- Melanoma
- Prostate cancer
- Others
- China Oncology Companion Diagnostic Market Technology Outlook (Revenue, USD Million , 2018-2030)
- Polymerase chain reaction (PCR)
- Next-generation sequencing (NGS)
- Immunohistochemistry (IHC)
- In situ hybridization (ISH)/Fluorescence in situ hybridization (FISH)
- Other technologies
Reasons to subscribe to oncology companion diagnostics market databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of oncology companion diagnostics market databook
- Our clientele includes a mix of oncology companion diagnostics market companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the China oncology companion diagnostics market, including forecasts for subscribers. This country databook contains high-level insights into China oncology companion diagnostics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
China Oncology Companion Diagnostic Market, 2018-2030 (US$M)
China oncology companion diagnostics market statistics, by product & service, 2018-2030 (US$M)
